Australia's largest stock trading and investment forum Australia's #1 stock forum

IHL

Click for more information

0.00%

4.1¢ incannex healthcare limited

General discussion, page-14987

First 14987 Last

Share
Profile

Follow
FreeBobby2002

890 Posts.

469

29/12/22

11:08

Post #: 65468091
Share

Originally posted by malkazoid: ↑

I had the same concern about APIRx initially, when there was a vacuum of information about their intentions towards the new drug candidates.
But that vacuum was filled, and I can't find fault with how management has proceeded with prioritisation and funding from the previous options raise.

Even if only one APIRx drug candidate eventuates, it will have been worth the acquisition AND the latest CR, if we want to argue that acquiring APIRx was a significant factor in needing the raise. With 22 candidates, some of them significantly de-risked already, and all benefitting from the inherent de-risking we all recognise in the long history of humanity's cannabinoid use and cannabinoid integration with human neurology, I'm comfortable calling the odds heavily in favour of the acquisition being an excellent move, long term. But as you say: time will tell.

Expand

I tend to agree but even if you like the longer term success it was a bad move for the share price in the medium term.

IHL Price at posting: 17.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

LU7

The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour

AHK

Ark Mines provides strategic update following mining lease submission

STK

Rogozna grows with gold equivalent grading 1.1g/t across 545.7m for Strickland

RCE

Recce progresses testing of gel to treat bacterial skin infections

TTT

Titomic jumps +6% as it incorporates Microsoft Hololens tech

There are more pages in this discussion • 5,455 more messages in this thread...

First 14987 Last

Add IHL (ASX) to my watchlist

SPONSORED BY